LONDON: Sinopharm's biotech unit has obtained regulatory approval for clinical trials of its mRNA COVID-19 vaccine against the Omicron variant, the company said on Friday.

The unit, based in the commercial hub of Shanghai, has built a research and development platform, as well as workshops with annual production capacity of 2 billion doses of mRNA vaccine, Sinopharm added.